GNVC Share Price

Open 6.53 Change Price %
High 6.91 1 Day 0.33 5.02
Low 6.53 1 Week -0.09 -1.29
Close 6.91 1 Month 0.41 6.31
Volume 20009 1 Year 6.39 1228.85
52 Week High 10.44
52 Week Low 0.27
GNVC Important Levels
Resistance 2 7.26
Resistance 1 7.12
Pivot 6.78
Support 1 6.70
Support 2 6.56
NASDAQ USA Most Active Stocks
SPWR 8.98 1.01%
TFSL 17.20 0.17%
RIGL 2.52 9.57%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
ADP 102.70 -0.29%
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
REGN 373.05 3.34%
More..
NASDAQ USA Top Gainers Stocks
TEAR 5.74 983.02%
CGEI 0.37 85.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
IMGN 3.28 21.03%
VOXX 5.05 20.24%
HAUP 0.06 20.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

GenVec, Inc. (NASDAQ: GNVC)

GNVC Technical Analysis 3
As on 27th Feb 2017 GNVC Share Price closed @ 6.91 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.71 & Buy for SHORT-TERM with Stoploss of 5.19 we also expect STOCK to react on Following IMPORTANT LEVELS.
GNVC Target for February
1st Target up-side 10.3
2nd Target up-side 13.08
3rd Target up-side 15.86
1st Target down-side 2.38
2nd Target down-side -0.4
3rd Target down-side -3.18
GNVC Other Details
Segment EQ
Market Capital 18522088.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.genvec.com
GNVC Address
GNVC
910 Clopper Road
Suite 220N
Gaithersburg, MD 20878
United States
Phone: 240-632-0740
Fax: 240-632-0735
GNVC Latest News
Interactive Technical Analysis Chart GenVec, Inc. ( GNVC NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on GenVec, Inc.
GNVC Business Profile
GenVec, Inc. develops gene-based pharmaceuticals and therapies for the treatment of major medical needs. The Company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates that address needs in the areas of cardiovascular disease, cancer and other therapeutic areas.